← Back to Clinical Trials
Recruiting NCT06156254

NCT06156254 Community Care Intervention to Decrease COVID-19 Vaccination Inequities

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06156254
Status Recruiting
Phase
Sponsor RAND
Condition COVID-19 Vaccination
Study Type INTERVENTIONAL
Enrollment 800 participants
Start Date 2023-09-21
Primary Completion 2026-06-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Community Health Worker Intervention to Enhance Vaccination Behavior (CHW-VB)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 800 participants in total. It began in 2023-09-21 with a primary completion date of 2026-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to find out if a community health workers (CHW) intervention conducted in Federally Qualified Health Centers (FQHCs) can increase the number of adults with chronic illnesses who are up-to-date with their COVID-19 and influenza vaccines.

Eligibility Criteria

Inclusion Criteria:18 years or older AND speak English or Spanish AND have no obvious physical or cognitive impairment that would make them unable to complete the assessment (as indicated by confusion or inability to understand the questions). Exclusion Criteria: not willing to consent OR acutely sick OR have high suicide risk Eligibility criteria: Have received a COVID-19 vaccine but not received an updated COVID-19 vaccine at the time of recruitment AND self-report being told by a physician they have one of the following health conditions; high blood pressure/hypertension OR diabetes OR asthma OR overweight/obese OR a one of the following mental health condition (probable depression, probable generalized anxiety, or probable PTSD) \-

Contact & Investigator

Central Contact

Andrea Cassells, MPH

✉ acass@cdnetwork.org

📞 212-382-0699

Principal Investigator

Marielena Lara, MD, MPH

PRINCIPAL INVESTIGATOR

RAND

Frequently Asked Questions

Who can join the NCT06156254 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying COVID-19 Vaccination. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06156254 currently recruiting?

Yes, NCT06156254 is actively recruiting participants. Contact the research team at acass@cdnetwork.org for enrollment information.

Where is the NCT06156254 trial being conducted?

This trial is being conducted at Brooklyn, United States, Brooklyn, United States, New York, United States, The Bronx, United States.

Who is sponsoring the NCT06156254 clinical trial?

NCT06156254 is sponsored by RAND. The principal investigator is Marielena Lara, MD, MPH at RAND. The trial plans to enroll 800 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology